Acumen Pharmaceuticals, Inc.
NASDAQ:ABOSBiotechnology
+$0.02 today
- Market cap
- $165.63M
- Beta
- 0.35
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$1.79
Volume 0.81M
Average 0.40M
ABOS Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Acumen Pharmaceuticals, Inc.NASDAQ: ABOS
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows in line with its trailing trend
Q1 FY2026 depreciation & amortization of $46K rose 2.2% year over year, behind the +3.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 2.2% from the prior quarter. Over 3 fiscal years it compounded at +2.9% a year.
Context
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +2.2% toward the trailing-twelve-month pace of +3.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 184K USD
- Year-over-year change
- +3.4%
- 4-year CAGR
- +160.4%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 184K | +3.4% |
| FY2024 | 2024-12-31 | 178K | -3.3% |
| FY2023 | 2023-12-31 | 184K | +8.9% |
| FY2022 | 2022-12-31 | 169K | +4125.0% |
| FY2021 | 2021-12-31 | 4K | — |
Depreciation & Amortization vs competitors
How ABOS compares with its peers on the latest reported figures
- ABOS's LTM Mar 2026 depreciation & amortization of $185K is the 7th highest of the 10 companies compared; the peer median is $5.03M.
- Its year-over-year change of +3.4% is the 3rd highest of 10, against a peer median of -3.9%.
- Over three fiscal years its annual growth of +2.9% compares with a peer median of +1.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $12.49M | -28.5% | -12.3% | 197.7% | |
| LTM Mar 2026 | $8.8M | +4.8% | +4.5% | 47.8% | |
| LTM Mar 2026 | $7.38M | -44.0% | +12.9% | 6.0% | |
| LTM Mar 2026 | $6.03M | -3.9% | +1.1% | 40.1% | |
| LTM Mar 2026 | $5.03M | +1.0% | -14.6% | 438.9% | |
| LTM Mar 2026 | $2.99M | -3.9% | -18.4% | — | |
| LTM Mar 2026 | $185K | +3.4% | +2.9% | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $53K | +241.9% | +136.6% | 0.4% |
| LTM Mar 2026 | $1K | -71.4% | — | 0.0% | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $0 | -100.0% | — | — |
| Peer median (excluding ABOS) | $5.03M | -3.9% | +1.1% | 40.1% | |
Competitors are the stored peer set for ABOS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 12.31M | 0 | 0 | 0 | 0 |
| Gross Profit | (12.31M) | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 12.31M | 32.36M | 42.32M | 93.8M | 104.89M |
| Selling, General & Admin | 7.28M | 12.88M | 18.82M | 20.22M | 18.95M |
| Operating Expenses | 7.28M | 45.24M | 61.14M | 114.02M | 123.83M |
| Depreciation & Amortization | 4K | 169K | 184K | 178K | 184K |
| EBITDA | (100.6M) | (42.69M) | (51.61M) | (98.08M) | (116.93M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (19.58M) | (45.24M) | (61.14M) | (114.02M) | (123.83M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 84K | 2.39M | 10.79M | 14.32M | 7.45M |
| Interest Expense | 0 | 0 | 581K | 4.07M | 4.22M |
| Other Income / Expenses | (81.02M) | 2.38M | 8.77M | 11.69M | 2.5M |
| Income Before Tax | (100.61M) | (42.86M) | (52.37M) | (102.33M) | (121.34M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (100.61M) | (42.86M) | (52.37M) | (102.33M) | (121.34M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.63) | (1.06) | (1.08) | (1.71) | (2.00) |
| EPS (Diluted) | (2.63) | (1.06) | (1.08) | (1.71) | (2.00) |
| Weighted Avg Shares | 38.27M | 40.6M | 48.49M | 60.01M | 60.56M |
| Weighted Avg Shares (Diluted) | 38.27M | 40.6M | 48.61M | 60.01M | 60.56M |
Acumen Pharmaceuticals, Inc.
NASDAQ:ABOS
Intrinsic Alpha fair value
Locked
Current Price
$2.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.